Acquired Company

Day One Biopharmaceuticals completed its acquisition of Mersana Therapeutics on January 6, 2026 for $25 per share in cash plus one non-tradable CVR worth up to $30.25 per share, for a total potential consideration of up to $55.25 per share.

Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It also developing DAY301, which is in phase I clinical trial for adult and pediatric cancers; and VRK1 Inhibitor which is in pre-clinical stage for adult and pediatric cancers. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California. Show more

1800 Sierra Point Parkway, Suite 217, Brisbane, CA, 94005, United States

https://dayonebio.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

1.201B

52 Wk Range

$5.63 - $13.20

Previous Close

$11.70

Open

$11.78

Volume

2,048,822

Day Range

$11.61 - $12.15

Enterprise Value

311M

Cash

451.6M

Avg Qtr Burn

-5.805M

Insider Ownership

16.97%

Institutional Own.

80.10%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
OJEMDA™ (Tovorafenib) (DAY101) Details Cancer, Pediatric low-grade glioma	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
OJEMDA™ (Tovorafenib) (DAY101) Details Cancer, Pediatric low-grade glioma	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Emi-Le/Emiltatug Ledadotin (Emi-Le) (B7-H4 ADC) Details Cancer, Adenoid Cystic Carcinoma	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
DAY301 (formerly MTX-13) Details Solid tumor/s	Phase 1a Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tovorafenib (DAY101) +/- Pimasertib Details Solid tumor/s, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.